Long-term Safety of Eplontersen Treated aTTR Patients and in Liver Transplant and Severely Hepatic Impaired Subpopulations
← catalyst calendarNCT07654855 · readout in 1,989 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →. With ICON Clinical Research.
Phase
—
Status
Not yet recruiting
Study type
Observational
Enrollment
320estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-09-01 | estimated | When the study began enrolling |
| Primary completion | 2032-01-29 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2032-01-29 | estimated | The whole study's end, after follow-up |
| First posted | 2026-06-17 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-06-17 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Transthyretin Amyloidosis
- Transthyretin Amyloidosis With Cardiomyopathy
- Transthyretin Amyloidosis With Polyneuropathy
Intervention
- Other: None ( observational study )
Primary outcomes
what the primary-completion date above is the date OFDemographic and clinical characteristics of eplontersen users, including the prevalence of prior liver transplant and severe hepatic impairment
measured Quarter 2 2026- Quarter 1 2032
Long term safety with patients who initiated eplonersen treatment
measured Quarter 2 2026- Quarter 1 2032
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed